Aspirin-induced Bcl-2 translocation and its phosphorylation in the nucleus trigger apoptosis in breast cancer cells

Experimental and Molecular Medicine

Volumn 45, Issue 10, 2013, Pages

  Choi, Bo Hwa ^a,b   Chakraborty, Goutam ^a   Baek, Kwanghee ^c   Yoon, Ho Sup ^a,c  

^a NANYANG TECHNOLOGICAL UNIVERSITY   (Singapore)

^b Pohang Center of Evolution of Biomaterials   (South Korea)

^c Kyung Hee University   (South Korea)

Author keywords

apoptosis; aspirin; Bcl 2; breast cancer; FKBP38; MCF 7

Indexed keywords

ACETYLSALICYLIC ACID; FK 506 BINDING PROTEIN; PROTEIN BCL 2; SALICYLIC ACID; SMALL INTERFERING RNA; FKBP8 PROTEIN, HUMAN; PROTEIN BINDING;

APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL; CANCER INHIBITION; CELL DEATH; CELL STRAIN MCF 7; CONTROLLED STUDY; GENE OVEREXPRESSION; GENE SILENCING; GENE TRANSLOCATION; HUMAN; HUMAN CELL; IN VITRO STUDY; MOLECULAR DOCKING; MOLECULAR MECHANICS; MOLECULARLY TARGETED THERAPY; NUCLEOTIDE SEQUENCE; PROTEIN INTERACTION; PROTEIN PHOSPHORYLATION; ACTIVE TRANSPORT; CELL NUCLEUS; DRUG EFFECTS; GENETICS; MCF 7 CELL LINE; METABOLISM; PHOSPHORYLATION; DRUG EFFECT; PROTEIN BINDING;

ACTIVE TRANSPORT, CELL NUCLEUS; APOPTOSIS; ASPIRIN; CELL NUCLEUS; HUMANS; MCF-7 CELLS; PHOSPHORYLATION; PROTEIN BINDING; PROTO-ONCOGENE PROTEINS C-BCL-2; TACROLIMUS BINDING PROTEINS;

EID: 84892404084     PISSN: 12263613     EISSN: 20926413     Source Type: Journal    
DOI: 10.1038/emm.2013.91     Document Type: Article

References (53)

1. Vane JR, Flower RJ, Botting RM. History of aspirin and its mechanism of action. Stroke 1990; 21: IV12-IV23.
2. Dalen JE. Aspirin to prevent heart attack and stroke: what's the right dose? Am J Med 2006; 119: 198-202.
3. Sandler RS, Galanko JC, Murray SC, Helm JF, Woosley JT. Aspirin and nonsteroidal anti-inflammatory agents and risk for colorectal adenomas. Gastroenterology 1998; 114: 441-447.
4. Harris RE, Namboodiri KK, Farrar WB. Nonsteroidal antiinflammatory drugs and breast cancer. Epidemiology 1996; 7: 203-205.
5. Dasgupta K, Di Cesar D, Ghosn J, Rajan R, Mahmud S, Rahme E. Association between nonsteroidal anti-inflammatory drugs and prostate cancer occurrence. Cancer J 2006; 12: 130-135.
6. Harris RE, Beebe-Donk J, Alshafie GA. Reduced risk of human lung cancer by selective cyclooxygenase 2 (COX-2) blockade: results of a case control study. Int J Biol Sci 2007; 3: 328-334.
7. McCaffrey P. Aspirin use reduces skin-cancer risk. Lancet Oncol 2006; 7: 16.
8. Lecomte M, Laneuville O, Ji C, DeWitt DL, Smith WL. Acetylation of human prostaglandin endoperoxide synthase-2 (cyclooxygenase-2) by aspirin. J Biol Chem 1994; 269: 13207-13215.
9. Tjiu JW, Liao YH, Lin SJ, Huang YL, Tsai WL, Chu CY et al. Cyclooxygenase-2 overexpression in human basal cell carcinoma cell line increases antiapoptosis, angiogenesis, and tumorigenesis. J Invest Dermatol 2006; 126: 1143-1151.
10. Wang X, Colby JK, Rengel RC, Fischer SM, Clinton SK, Klein RD. Overexpression of cyclooxygenase-2 (COX-2) in the mouse urinary bladder induces the expression of immune-and cell proliferation-related genes. Mol Carcinog 2009; 48: 1-13.
11. Sano H, Kawahito Y, Wilder RL, Hashiramoto A, Mukai S, Asai K et al. Expression of cyclooxygenase-1 and-2 in human colorectal cancer. Cancer Res 1995; 55: 3785-3789.
12. Hida T, Yatabe Y, Achiwa H, Muramatsu H, Kozaki K, Nakamura S et al. Increased expression of cyclooxygenase 2 occurs frequently in human lung cancers, specifically in adenocarcinomas. Cancer Res 1998; 58: 3761-3764.
13. Hwang D, Scollard D, Byrne J, Levine E. Expression of cyclooxygenase-1 and cyclooxygenase-2 in human breast cancer. J Natl Cancer Inst 1998; 90: 455-460.
14. Chan G, Boyle JO, Yang EK, Zhang F, Sacks PG, Shah JP et al. Cyclooxygenase-2 expression is up-regulated in squamous cell carcinoma of the head and neck. Cancer Res 1999; 59: 991-994.
15. Achiwa H, Yatabe Y, Hida T, Kuroishi T, Kozaki K, Nakamura S et al. Prognostic significance of elevated cyclooxygenase 2 expression in primary, resected lung adenocarcinomas. Clin Cancer Res 1999; 5: 1001-1005.
16. Ristimaki A, Sivula A, Lundin J, Lundin M, Salminen T, Haglund C et al. Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer. Cancer Res 2002; 62: 632-635.
17. Hanif R, Pittas A, Feng Y, Koutsos MI, Qiao L, Staiano-Coico L et al. Effects of nonsteroidal anti-inflammatory drugs on proliferation and on induction of apoptosis in colon cancer cells by a prostaglandin-independent pathway. Biochem Pharmacol 1996; 52: 237-245.
18. Zhang X, Morham SG, Langenbach R, Young DA. Malignant transformation and antineoplastic actions of nonsteroidal antiinflammatory drugs (NSAIDs) on cyclooxygenase-null embryo fibroblasts. J Exp Med 1999; 190: 451-459.
19. Kopp E, Ghosh S. Inhibition of NF-kappa B by sodium salicylate and aspirin. Science (New York, NY) 1994; 265: 956-959.
20. Dikshit P, Chatterjee M, Goswami A, Mishra A, Jana NR. Aspirin induces apoptosis through the inhibition of proteasome function. J Biol Chem 2006; 281: 29228-29235.
21. Zhang L, Yu J, Park BH, Kinzler KW, Vogelstein B. Role of BAX in the apoptotic response to anticancer agents. Science (New York, NY) 2000; 290: 989-992.
22. Kim KM, Song JJ, An JY, Kwon YT, Lee YJ. Pretreatment of acetylsalicylic acid promotes tumor necrosis factor-related apoptosis-inducing ligandinduced apoptosis by down-regulating BCL-2 gene expression. J Biol Chem 2005; 280: 41047-41056.
23. Yin MJ, Yamamoto Y, Gaynor RB. The anti-inflammatory agents aspirin and salicylate inhibit the activity of I(kappa)B kinase-beta. Nature 1998; 396: 77-80.
24. Gao J, Niwa K, Sun W, Takemura M, Lian Z, Onogi K et al. Non-steroidal anti-inflammatory drugs inhibit cellular proliferation and upregulate cyclooxygenase-2 protein expression in endometrial cancer cells. Cancer Sci 2004; 95: 901-907.
25. Zhou XM, Wong BC, Fan XM, Zhang HB, Lin MC, Kung HF et al. Non-steroidal anti-inflammatory drugs induce apoptosis in gastric cancer cells through upregulation of bax and bak. Carcinogenesis 2001; 22: 1393-1397.
26. Borthwick GM, Johnson AS, Partington M, Burn J, Wilson R, Arthur HM. Therapeutic levels of aspirin and salicylate directly inhibit a model of angiogenesis through a Cox-independent mechanism. FASEB J 2006; 20: 2009-2016.
27. Higgs GA, Salmon JA, Henderson B, Vane JR. Pharmacokinetics of aspirin and salicylate in relation to inhibition of arachidonate cyclooxygenase and antiinflammatory activity. Proc Natl Acad Sci USA 1987; 84: 1417-1420.
28. Din FV, Dunlop MG, Stark LA. Evidence for colorectal cancer cell specificity of aspirin effects on NF kappa B signalling and apoptosis. Br J Cancer 2004; 91: 381-388.
29. Kang CB, Tai J, Chia J, Yoon HS. The flexible loop of Bcl-2 is required for molecular interaction with immunosuppressant FK-506 binding protein 38 (FKBP38). FEBS Lett 2005; 579: 1469-1476.
30. Choi BH, Hur EM, Lee JH, Jun DJ, Kim KT. Protein kinase Cdeltamediated proteasomal degradation of MAP kinase phosphatase-1 contributes to glutamate-induced neuronal cell death. J Cell Sci 2006; 119: 1329-1340.
31. Choi BH, Kim W, Wang QC, Kim DC, Tan SN, Yong JW et al. Kinetin riboside preferentially induces apoptosis by modulating Bcl-2 family proteins and caspase-3 in cancer cells. Cancer Lett 2008; 261: 37-45.
32. Shirane M, Nakayama KI. Inherent calcineurin inhibitor FKBP38 targets Bcl-2 to mitochondria and inhibits apoptosis. Nat Cell Biol 2003; 5: 28-37.
33. Massaad CA, Portier BP, Taglialatela G. Inhibition of transcription factor activity by nuclear compartment-associated Bcl-2. J Biol Chem 2004; 279: 54470-54478.
34. Portier BP, Taglialatela G. Bcl-2 localized at the nuclear compartment induces apoptosis after transient overexpression. J Biol Chem 2006; 281: 40493-40502.
35. Srivastava RK, Mi QS, Hardwick JM, Longo DL. Deletion of the loop region of Bcl-2 completely blocks paclitaxel-induced apoptosis. Proc Natl Acad Sci USA 1999; 96: 3775-3780.
36. Yamamoto K, Ichijo H, Korsmeyer SJ. BCL-2 is phosphorylated and inactivated by an ASK1/Jun N-terminal protein kinase pathway normally activated at G(2)/M. Mol Cell Biol 1999; 19: 8469-8478.
37. Basu A, Haldar S. Microtubule-damaging drugs triggered bcl2 phosphorylation-requirement of phosphorylation on both serine-70 and serine-87 residues of bcl2 protein. Int J Oncol 1998; 13: 659-664.
38. Ruchaud S, Korfali N, Villa P, Kottke TJ, Dingwall C, Kaufmann SH et al. Caspase-6 gene disruption reveals a requirement for lamin A cleavage in apoptotic chromatin condensation. EMBO J 2002; 21: 1967-1977.
39. Jacobs EJ, Thun MJ, Bain EB, Rodriguez C, Henley SJ, Calle EE. A large cohort study of long-term daily use of adult-strength aspirin and cancer incidence. J Natl Cancer Inst 2007; 99: 608-615.
40. Zhang SM, Cook NR, Manson JE, Lee IM, Buring JE. Low-dose aspirin and breast cancer risk: results by tumour characteristics from a randomised trial. Br J Cancer 2008; 98: 989-991.
41. Gonzalez-Perez A, Garcia Rodriguez LA, Lopez-Ridaura R. Effects of nonsteroidal anti-inflammatory drugs on cancer sites other than the colon and rectum: a meta-analysis. BMC Cancer 2003; 3: 28.
42. Takkouche B, Regueira-Mendez C, Etminan M. Breast cancer and use of nonsteroidal anti-inflammatory drugs: a meta-analysis. J Natl Cancer Inst 2008; 100: 1439-1447.
43. Liu J, Farmer JD Jr, Lane WS, Friedman J, Weissman I, Schreiber SL. Calcineurin is a common target of cyclophilin-cyclosporin A and FKBPFK506 complexes. Cell 1991; 66: 807-815.
44. Schreiber SL. Immunophilin-sensitive protein phosphatase action in cell signaling pathways. Cell 1992; 70: 365-368.
45. Kang CB, Hong Y, Dhe-Paganon S, Yoon HS. FKBP family proteins: immunophilins with versatile biological functions. Neurosignals 2008; 16: 318-325.
46. Kaufmann JA, Perez M, Zhang W, Bickford PC, Holmes DB, Taglialatela G. Free radical-dependent nuclear localization of Bcl-2 in the central nervous system of aged rats is not associated with Bcl-2-mediated protection from apoptosis. J Neurochem 2003; 87: 981-994.
47. Portier BP, Taglialatela G. Bcl-2 localized at the nuclear compartment induces apoptosis after transient overexpression. J Biol Chem 2006; 281: 40493-40502.
48. Leek RD, Kaklamanis L, Pezzella F, Gatter KC, Harris A. L. bcl-2 in normal human breast and carcinoma, association with oestrogen receptor-positive, epidermal growth factor receptor-negative tumours and in situ cancer. Br J Cancer 1994; 69: 135-139.
49. Alireza A, Raheleh S, Abbass R, Mojgan M, Mohamadreza M, Gholamreza M et al. An immunohistochemistry study of tissue bcl-2 expression and its serum levels in breast cancer patients. Ann NY Acad Sci 2008; 1138: 114-120.
50. Bilalovic N, Vranić S, Hasanagić S, Basić H, Tatarević A, Beslija S et al. The Bcl-2 protein: a prognostic indicator strongly related to ER and PR in breast cancer. Bosn J Basic Med Sci 2004; 4: 5-12.
51. Nadler Y, Camp RL, Giltnane JM, Moeder C, Rimm DL, Kluger HM et al. Expression patterns and prognostic value of Bag-1 and Bcl-2 in breast cancer. Breast Cancer Res 2008; 10: R35.
52. Kwon G, Hill JR, Corbett JA, McDaniel ML. Effects of aspirin on nitric oxide formation and de novo protein synthesis by RINm5F cells and rat islets. Mol Pharmacol 1997; 52: 398-405.
53. Silva AM, Wang D, Komar AA, Castilho BA, Williams BR. Salicylates trigger protein synthesis inhibition in a protein kinase R-like endoplasmic reticulum kinase-dependent manner. J Biol Chem 2007; 282: 10164-10171.